ES2170479T3 - Agente viral terapeutico que detiene el desarrollo de tumores. - Google Patents

Agente viral terapeutico que detiene el desarrollo de tumores.

Info

Publication number
ES2170479T3
ES2170479T3 ES98907023T ES98907023T ES2170479T3 ES 2170479 T3 ES2170479 T3 ES 2170479T3 ES 98907023 T ES98907023 T ES 98907023T ES 98907023 T ES98907023 T ES 98907023T ES 2170479 T3 ES2170479 T3 ES 2170479T3
Authority
ES
Spain
Prior art keywords
tumors
stops
development
viral agent
therapeutic viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98907023T
Other languages
English (en)
Inventor
Alexander Fred Markham
David Mark Meredith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Leeds
Original Assignee
University of Leeds
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Leeds filed Critical University of Leeds
Application granted granted Critical
Publication of ES2170479T3 publication Critical patent/ES2170479T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un herpesvirus equino que se ha modificado por ingeniería genética o alterado de modo que exhiba una sensibilidad potenciada frente a un agente antiherpético, siendo capaz del virus de replicarse en tejido humano, para uso como compuesto farmacéutico, opcionalmente para uso en el tratamiento de tumores.
ES98907023T 1997-02-27 1998-02-24 Agente viral terapeutico que detiene el desarrollo de tumores. Expired - Lifetime ES2170479T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9704046.3A GB9704046D0 (en) 1997-02-27 1997-02-27 Arrestable therapeutic

Publications (1)

Publication Number Publication Date
ES2170479T3 true ES2170479T3 (es) 2002-08-01

Family

ID=10808384

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98907023T Expired - Lifetime ES2170479T3 (es) 1997-02-27 1998-02-24 Agente viral terapeutico que detiene el desarrollo de tumores.

Country Status (11)

Country Link
EP (1) EP0979093B1 (es)
JP (1) JP2001513634A (es)
AT (1) ATE210990T1 (es)
AU (1) AU6301398A (es)
CA (1) CA2280690A1 (es)
DE (1) DE69803052T2 (es)
DK (1) DK0979093T3 (es)
ES (1) ES2170479T3 (es)
GB (1) GB9704046D0 (es)
PT (1) PT979093E (es)
WO (1) WO1998037905A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2695101A (en) 2000-01-21 2001-07-31 Biovex Ltd Virus strains
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0668355B1 (en) * 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
IL118942A (en) * 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
GB9626029D0 (en) * 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors

Also Published As

Publication number Publication date
AU6301398A (en) 1998-09-18
ATE210990T1 (de) 2002-01-15
WO1998037905A1 (en) 1998-09-03
CA2280690A1 (en) 1998-09-03
GB9704046D0 (en) 1997-04-16
DK0979093T3 (da) 2002-04-02
EP0979093B1 (en) 2001-12-19
PT979093E (pt) 2002-06-28
EP0979093A1 (en) 2000-02-16
DE69803052T2 (de) 2002-07-25
JP2001513634A (ja) 2001-09-04
DE69803052D1 (de) 2002-01-31

Similar Documents

Publication Publication Date Title
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
ATE324119T1 (de) Verwendung von saccharid-konjugaten
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
TR199901174T2 (xx) Yeni heterosiklilmetil-ikameli pirazol t�revleri.
ATE232396T1 (de) Oxydiertes thymosin beta 4
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
ATE408601T1 (de) Fredericamycin-derivate
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BRPI0411078A (pt) ligantes de receptores de canabinóides e seus usos
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
TR200002784T2 (tr) Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
NO20055832L (no) Fremstilling og anvendelse av arylalkylsyrederivater for behandling av fedme
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
AU2001235006A1 (en) Prophylactic and therapeutic monoclonal antibodies
DE69629570D1 (de) 3'utr des menschliches prohibitin-gens
BR0010702A (pt) Novas quinonas como terapias de doenças
TR200100637T2 (tr) Yeni doğal ürün türevleri
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
ES2170479T3 (es) Agente viral terapeutico que detiene el desarrollo de tumores.
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 979093

Country of ref document: ES